Research Analysts’ Recent Ratings Changes for Protagonist Therapeutics (PTGX)

A number of research firms have changed their ratings and price targets for Protagonist Therapeutics (NASDAQ: PTGX):

• 7/17/2026 – Protagonist Therapeutics was given a new $165.00 price target by Johnson Rice.
• 7/17/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $119.00 to $151.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Protagonist Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/7/2026 – Protagonist Therapeutics had its price target raised by Truist Financial Corporation from $121.00 to $145.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Protagonist Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 6/27/2026 – Protagonist Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Insider Activity

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the transaction, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bryan Giraudo sold 36,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $100.14, for a total transaction of $3,605,040.00. Following the transaction, the director directly owned 27,825 shares in the company, valued at approximately $2,786,395.50. The trade was a 56.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 161,130 shares of company stock valued at $16,355,220. Company insiders own 5.19% of the company’s stock.

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.